Anti-infectives in Drug Delivery-Overcoming the Gram-Negative Bacterial Cell Envelope

Florian Graef1, Sarah Gordon1, Claus-Michael Lehr2,3

  • 1Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarbrücken, Germany.

Insights

Treating Gram-negative bacterial infections is challenging due to poor drug penetration. New models and advanced delivery systems, like particle carriers, are needed to improve anti-infective efficacy and combat resistance.

Area of Science:

  • Microbiology and Infectious Diseases
  • Drug Delivery and Nanotechnology
  • Bacterial Pathogenesis

Background:

  • Gram-negative bacteria pose a significant global health threat, particularly in healthcare settings.
  • Ineffective treatment of Gram-negative infections stems from the bacterial cell envelope's barrier properties and resistance mechanisms.
  • Current models for studying anti-infective transport across bacterial envelopes have limitations.

Purpose of the Study:

  • To review and evaluate current bacterial permeation models and advanced anti-infective formulation strategies.
  • To highlight the need for improved methods to characterize anti-infective permeation.
  • To identify future directions for enhancing anti-infective delivery and overcoming bacterial resistance.

Main Methods:

  • Review of existing in vitro, in silico, and in cellulo models for studying anti-infective permeation.
  • Evaluation of advanced anti-infective formulation strategies, including particle-based carriers and combination therapies.
  • Analysis of current challenges and limitations in drug delivery across the Gram-negative bacterial envelope.

Main Results:

  • Existing models for assessing anti-infective permeation have significant drawbacks.
  • Particle-based carrier systems show potential for overcoming drug delivery challenges and enabling targeted delivery.
  • Formulations combining efflux pump inhibitors or antimicrobial peptides with anti-infectives can restore antibiotic activity against resistant strains.

Conclusions:

  • There is a critical need for novel approaches to comprehensively characterize anti-infective permeation processes.
  • Advanced formulation strategies, particularly particle-based carriers, are essential for improving anti-infective efficacy.
  • Further research is required to design carriers that enhance transport across bacterial envelopes and target difficult-to-treat infections.

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
22
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
24
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
299
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
305
Bacterial Cell Wall01:22

Bacterial Cell Wall

The bacterial cell wall is an essential structural component that encases the plasma membrane, preserving cellular integrity, determining shape, and protecting against osmotic stress. This rigid yet flexible structure primarily comprises peptidoglycan, a polymer that forms a mesh-like matrix conferring mechanical strength and flexibility.Peptidoglycan Composition and StructurePeptidoglycan, the core of the bacterial cell wall, comprises alternating units of N-acetylglucosamine (NAG) and...
5.1K